These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 30848108)

  • 1. Anticancer drugs approved by the Food and Drug Administration for gastrointestinal malignancies: Clinical benefit and price considerations.
    Jiang DM; Chan KKW; Jang RW; Booth C; Liu G; Amir E; Mason R; Everest L; Elimova E
    Cancer Med; 2019 Apr; 8(4):1584-1593. PubMed ID: 30848108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000-2015.
    Vivot A; Jacot J; Zeitoun JD; Ravaud P; Crequit P; Porcher R
    Ann Oncol; 2017 May; 28(5):1111-1116. PubMed ID: 28453694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration.
    Molto C; Hwang TJ; Borrell M; Andres M; Gich I; Barnadas A; Amir E; Kesselheim AS; Tibau A
    Cancer; 2020 Oct; 126(19):4390-4399. PubMed ID: 32697362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploration of the ASCO and ESMO Value Frameworks for Antineoplastic Drugs.
    Becker DJ; Lin D; Lee S; Levy BP; Makarov DV; Gold HT; Sherman S
    J Oncol Pract; 2017 Jul; 13(7):e653-e665. PubMed ID: 28493760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Value of Molecular Targets and FDA-Approved Genome-Targeted Cancer Therapies.
    Tibau A; Hwang TJ; Molto C; Avorn J; Kesselheim AS
    JAMA Oncol; 2024 May; 10(5):634-641. PubMed ID: 38573645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration.
    Tibau A; Molto C; Ocana A; Templeton AJ; Del Carpio LP; Del Paggio JC; Barnadas A; Booth CM; Amir E
    J Natl Cancer Inst; 2018 May; 110(5):486-492. PubMed ID: 29244173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis.
    Vokinger KN; Hwang TJ; Grischott T; Reichert S; Tibau A; Rosemann T; Kesselheim AS
    Lancet Oncol; 2020 May; 21(5):664-670. PubMed ID: 32359489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Examining Trends in Cost and Clinical Benefit of Novel Anticancer Drugs Over Time.
    Saluja R; Arciero VS; Cheng S; McDonald E; Wong WWL; Cheung MC; Chan KKW
    J Oncol Pract; 2018 May; 14(5):e280-e294. PubMed ID: 29601250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks.
    Del Paggio JC; Sullivan R; Schrag D; Hopman WM; Azariah B; Pramesh CS; Tannock IF; Booth CM
    Lancet Oncol; 2017 Jul; 18(7):887-894. PubMed ID: 28583794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Long-term Survival Benefits in Trials of Immune Checkpoint Inhibitor vs Non-Immune Checkpoint Inhibitor Anticancer Agents Using ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale.
    Everest L; Shah M; Chan KKW
    JAMA Netw Open; 2019 Jul; 2(7):e196803. PubMed ID: 31290990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review.
    Arciero V; Delos Santos S; Koshy L; Rahmadian A; Saluja R; Everest L; Parmar A; Chan KKW
    JAMA Netw Open; 2021 Feb; 4(2):e2033004. PubMed ID: 33570573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration.
    Liang F; Zhang S; Wang Q; Li W
    BMC Cancer; 2020 Aug; 20(1):823. PubMed ID: 32867707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient Participation in Clinical Trials of Oncology Drugs and Biologics Preceding Approval by the US Food and Drug Administration.
    Hutchinson N; Carlisle B; Doussau A; Bosan R; Gumnit E; MacPherson A; Fergusson DA; Kimmelman J
    JAMA Netw Open; 2021 May; 4(5):e2110456. PubMed ID: 34003270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in the Price per Median and Mean Life-Year Gained Among Newly Approved Cancer Therapies 1995 to 2017.
    Chen AJ; Hu X; Conti RM; Jena AB; Goldman DP
    Value Health; 2019 Dec; 22(12):1387-1395. PubMed ID: 31806195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical benefit, reimbursement outcomes, and prices of FDA-approved cancer drugs reviewed through Project Orbis in the USA, Canada, England, and Scotland: a retrospective, comparative analysis.
    Jenei K; Gentilini A; Haslam A; Prasad V
    Lancet Oncol; 2024 Aug; 25(8):979-988. PubMed ID: 39004098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Cancer Drug Approvals From the Perspective of a Universal Healthcare System: Analyses of the Pan-Canadian Oncology Drug Review Recommendations.
    Niraula S; Nugent Z
    J Natl Compr Canc Netw; 2018 Dec; 16(12):1460-1466. PubMed ID: 30545993
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016.
    Ladanie A; Schmitt AM; Speich B; Naudet F; Agarwal A; Pereira TV; Sclafani F; Herbrand AK; Briel M; Martin-Liberal J; Schmid T; Ewald H; Ioannidis JPA; Bucher HC; Kasenda B; Hemkens LG
    JAMA Netw Open; 2020 Nov; 3(11):e2024406. PubMed ID: 33170262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of the ESMO Magnitude of Clinical Benefit Scale to assess the clinical benefit of antibody drug conjugates in solid cancer: a systematic descriptive analysis of phase III and pivotal phase II trials.
    Ding L; Yuan X; Wang Y; Shen Z; Wu P
    BMJ Open; 2024 Jun; 14(6):e077108. PubMed ID: 38851227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Survey of Survival Outcomes for Targeted Cancer Drugs Approved by the US Food and Drug Administration.
    He Q; Li Q; Lv F; Kaitin KI; Shao L
    Ther Innov Regul Sci; 2021 Jul; 55(4):676-684. PubMed ID: 33683659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Price analysis of multiple sclerosis disease-modifying therapies marketed in the United States.
    Bin Sawad A; Seoane-Vazquez E; Rodriguez-Monguio R; Turkistani F
    Curr Med Res Opin; 2016 Nov; 32(11):1783-1788. PubMed ID: 27359262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.